- Home
- NEE vs AMGN Comparison
NEE vs AMGN Comparison
Compare NEE & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEE | AMGN |
|---|---|---|
| Founded | 1925 | 1980 |
| Country | United States | United States |
| Employees | 17400 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0B | 188.7B |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | NEE | AMGN |
|---|---|---|
| Price | $86.78 | $351.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 19 |
| Target Price | $95.67 | ★ $351.05 |
| AVG Volume (30 Days) | ★ 10.7M | 2.8M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 2.65% | ★ 2.98% |
| EPS Growth | N/A | ★ 88.23 |
| EPS | N/A | ★ 3.34 |
| Revenue | N/A | ★ $25,424,000,000.00 |
| Revenue This Year | $15.92 | $5.00 |
| Revenue Next Year | $8.48 | $2.45 |
| P/E Ratio | ★ $27.64 | $103.86 |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $67.20 | $269.77 |
| 52 Week High | $98.75 | $391.29 |
Technical Indicators
Market Signals| Indicator | NEE | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 57.02 |
| Support Level | $86.63 | $334.95 |
| Resistance Level | $86.99 | $357.01 |
| Average True Range (ATR) | 1.45 | 8.70 |
| MACD | 0.42 | 0.41 |
| Stochastic Oscillator | 78.81 | 70.42 |
Price Performance
Historical ComparisonAbout NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to over 6 million customer accounts in Florida and owns 36 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with nearly 40 GW of generation capacity, including natural gas, nuclear, wind, and solar.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.